TRADE POLICY | 2026-02-23

Recovering IEEPA Tariff Duties on Pharmaceutical Imports: A Practitioner's Guide to the WTO Pharmaceutical Agreement, Section 232 Investigation, and Refund Mechanisms After Learning Resources, Inc. v. Trump

Practitioner's guide to IEEPA tariff refund claims for pharmaceutical importers, examining the unique advantages of the WTO Pharmaceutical Agreement zero-MFN framework, the Section 122 exemption for pharmaceuticals, the pending Section 232 investigation threatening 100% tariffs, and the critical Chapter 29 vs. Chapter 30 classification distinction.

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published · Updated

The pharmaceutical sector occupies a uniquely favorable position in the post-Learning Resources tariff landscape. Unlike virtually every other import sector, pharmaceuticals classified under HTSUS Chapter 30 benefit from zero MFN duty rates under the WTO Pharmaceutical Agreement, creating a refund...

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301